Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Active:	No
Cancer Type:	Leukemia Lymphoma Multiple Myeloma Non-Hodgkin Lymphoma Plasma cell neoplasm	NCT ID:	NCT05024045
Trial Phases:	Phase I	Protocol IDs:	LOXO-BCL-20001 (primary) NCI-2021-10661 2021-000060-30 J3N-OX-JZRA
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Eli Lilly and Company
NCI Full Details:	http://clinicaltrials.gov/show/NCT05024045

Summary

The purpose of this study is to find out whether the study drug, LOXO-338, is safe and
effective in patients with advanced blood cancer. Patients must have already received
standard therapy. The study may last up to approximately 3 years.

Objectives

This study will be conducted in 2 parts. Part 1 will evaluate LOXO-338 as monotherapy. If
safety and initial evidence of efficacy of LOXO-338 monotherapy are confirmed, part 2 will
evaluate the combination of LOXO-338 with the highly selective, noncovalent Bruton's tyrosine
kinase (BTK) inhibitor, pirtobrutinib (LOXO-305).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.